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DC-SIGN, a Dendritic Cell±Specific
HIV-1-Binding Protein that Enhances
trans-Infection of T Cells
vague, but based on anatomical distribution of different
hematopoietic lineage cells and on in vitro infectivity
studies it has been inferred that immature dendritic cells
(DC) residing in the skin and at mucosal surfaces are
the first cells targeted by HIV-1. DC are the most potent
Teunis B. H. Geijtenbeek,* Douglas S. Kwon,§
Ruurd Torensma,* Sandra J. van Vliet,*
Gerard C. F. van Duijnhoven,* Jeena Middel,³
Ine L. M. H. A. Cornelissen,² Hans S. L. M. Nottet,³
Vineet N. KewalRamani,§ Dan R. Littman,§k
antigen-presenting cells in vivo (Valitutti et al., 1995;Carl G. Figdor,* and Yvette van Kooyk*#
Banchereau and Steinman, 1998). Immature DC in pe-*Department of Tumor Immunology
ripheral tissues capture antigens efficiently and have²Department of Pathology
the unique capacity to subsequently migrate to the TUniversity Medical Center St. Radboud
cell areas of secondary lymphoid organs. As the cellsPhilips van Leydenlaan 25
travel, they mature and alter their expression profile ofNijmegen 6525 EX
cell surface molecules, including chemokine receptors,The Netherlands
lose their ability to take up antigen, and acquire compe-³Eykman-Winkler Institute of Microbiology
tence to attract and activate resting T cells in the lymphUniversity Hospital Utrecht
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Piperno et al., 1996; Rubbert et al., 1998), and they have
been reported to be infectable with R5 strains of HIV-1.
In contrast, immature DC do not express CXCR4 andSummary
are resistant to infection with X4 isolates of HIV-1
(Weissman et al., 1995; Blauvelt et al., 1997; Granelli-Dendritic cells (DC) capture microorganisms that enter
Piperno et al., 1998). Entry of HIV-1 into immature DCperipheral mucosal tissues and then migrate to sec-
has also been reported to proceed through a CD4-inde-ondary lymphoid organs, where they present these
pendent mechanism (Blauvelt et al., 1997), suggestingin antigenic form to resting T cells and thus initiate
that receptors other than CD4 could be involved. Thereadaptive immune responses. Here, we describe the
have been conflicting reports regarding the significanceproperties of a DC-specific C-type lectin, DC-SIGN,
of HIV-1 replication within DC (Cameron et al., 1994;that is highly expressed on DC present in mucosal
Ayehunie et al., 1997; Canque et al., 1999). Althoughtissues and binds to the HIV-1 envelope glycoprotein
replication can be observed in some circumstances, itgp120. DC-SIGN does not function as a receptor for
has also been reported that, in immature DC, replicationviral entry into DC but instead promotes efficient infec-
is incomplete and that only early HIV-1 genes are tran-tion in trans of cells that express CD4 and chemokine
scribed.receptors. We propose that DC-SIGN efficiently cap-
It has been proposed that virus-infected immature DCtures HIV-1 in the periphery and facilitates its transport
migrate to the draining lymph nodes where they initiateto secondary lymphoid organs rich in T cells, to en-
both a primary antiviral immune response and a vigoroushance infection in trans of these target cells.
productive infection of T cells, allowing systemic distri-
bution of HIV-1 (Cameron et al., 1992; Weissman et al.,
Introduction 1995; Granelli-Piperno et al., 1999). However, in a nonhu-
man primate model of mucosal infection with the simian
Transmission of human immunodeficiency virus type 1 immunodeficiency virus, it has been difficult to demon-
(HIV-1) infection in humans requires the dissemination strate productive infection of DC despite rapid dissemi-
of virus from sites of infection at mucosal surfaces to T nation of virus (Stahl-Hennig et al., 1999). Other efforts
cell zones in secondary lymphoid organs, where exten- to model primary HIV-1 infection in vitro by exposing
sive viral replication occurs in CD41 T-helper cells DC derived from skin or blood to HIV-1 have indicated
(Fauci, 1996). These cells express both CD4 and the that these cells are poorly infected. Nevertheless, only
chemokine receptor CCR5, which together form the re- DC and not other leukocytes, including monocytes,
ceptor complex required for entry by the R5 viral isolates macrophages, B cells, and T cells, were able to induce
that are prevalent early after infection (Dragic et al., high levels of infection upon coculture with mitogen-
1996; Lu et al., 1997; Littman, 1998). Viruses with tropism activated CD41 T cells after being pulsed with HIV-1
for other chemokine receptors, particularly CXCR4, are (Cameron et al., 1992, 1992b, 1996; Weissman et al.,
rarely transmitted and generally appear only late in in- 1995; Blauvelt et al., 1997; Granelli-Piperno et al., 1999).
fection. In an early study, Cameron et al. (1992) proposed that
The mechanism of early viral dissemination remains DC have a unique ability to ªcatalyzeº infection of T cells
with HIV but do not become infected themselves.
The mechanism by which DC capture HIV-1 and pro-# To whom correspondence should be addressed: (e-mail: y.vankooyk@
dent.kun.nl). mote infection of CD41 T cells has not been elucidated,
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Figure 1. DC-SIGN Is a DC-Specific Recep-
tor for HIV-1 gp120
(A) DC-SIGN is expressed specifically by DC.
Immature DC, cultured from monocytes in the
presence of GM-CSF and IL-4, express high
levels of DC-SIGN, whereas resting periph-
eral blood lymphocytes and monocytes do
not express DC-SIGN. Expression of DC-
SIGN (AZN-D1) was determined by FACScan
analysis. One representative experiment out
of three is shown.
(B) DC-SIGN, but not CD4, mediates binding
of HIV-1 gp120 to DC. DC were allowed to
bind HIV-1 gp120-coated fluorescent beads.
Adhesion was blocked by anti-DC-SIGN anti-
bodies (20 mg/ml), mannan (20 mg/ml), and
EGTA (5 mM), and not by neutralizing anti-
CD4 antibodies (20 mg/ml). One representa-
tive experiment out of three is shown.
(C) Immature DC express low levels of CD4
(RPA-T4) and CCR5 (2D7/CCR5) and high lev-
els of DC-SIGN (AZN-D1). THP-1 cells stably
transfected with DC-SIGN (THP-DC-SIGN)
express high levels of DC-SIGN (AZN-D1)
while CD4 and CCR5 are not expressed (filled
histograms). Antibodies against CD4 and DC-
SIGN were isotype matched, and the appro-
priate isotype controls are represented by
dotted lines.
(D) DC-SIGN transfectants (THP-DC-SIGN)
bind HIV-1 gp120. THP-DC-SIGN and mock
transfectants were allowed to bind HIV-
1gp120-coated fluorescent beads. Adhesion
was blocked by anti-DC-SIGN antibodies (20
mg/ml) and EGTA (5mM) and not by neutraliz-
ing anti-CD4 (RPA-T4) antibodies (20 mg/ml).
One representative experiment out of three
is shown.
and it has been unclear whether there is specificity in (Geijtenbeek et al., 2000). Flow cytometric analysis of
an extensive panel of hematopoietic cells with anti-DC-the interaction of DC with virus. In the accompanying
paper, we describe the identification of a DC-specific SIGN antibodies demonstrated that DC-SIGN is prefer-
entially expressed on in vitro cultured DC but not onC-type lectin, designated DC-SIGN, that binds with high
affinity to ICAM-3 present on resting T cells (Geijtenbeek other leukocytes, such as monocytes and peripheral
blood lymphocytes (PBL) (Figure 1A). Identification ofet al., 2000 [this issue of Cell]). Nucleotide sequence
analysis of the cDNA indicated that this molecule is DC-SIGN by peptide amino acid sequencing of the 44
kDa immunoprecipitated protein revealed it to be 100%identical to a previously described HIV-1 gp120-binding
C-type lectin (Curtis et al., 1992) isolated from a placen- identical in its amino acid sequence to the HIV-1 enve-
lope glycoprotein gp120-binding C-type lectin pre-tal cDNA library. Here, we demonstrate that this HIV-1-
binding protein, which is highly expressed on DC pres- viously isolated from a placental cDNA library (Curtis et
ent at mucosal sites, specifically captures HIV-1 and al., 1992). To determine whether this molecule has a role
promotes infection in trans of target cells that express in binding of HIV to DC, we used a flow cytometric
CD4 and appropriate chemokine receptors. Our findings adhesion assay (Geijtenbeek et al., 1999) to examine
suggest that, during transmission of HIV-1, the virus the ability of HIV-1 gp120-coated fluorescent beads to
initially binds to mucosal DC through DC-SIGN, allowing bind to immature DC (Figure 1B). The gp120-coated
subsequent transport to secondary lymphoid organs beads bound efficiently to the DC, and the binding was
and highly efficient infection of CD41 T cells by a novel completely blocked by the anti-DC-SIGN antibodies
trans infection mechanism. AZN-D1 and AZN-D2. In contrast, neutralizing anti-CD4
antibodies had no effect on gp120 binding to DC. This
Results result indicates that, although the primary HIV-1 recep-
tor CD4 is expressed on DC (Figure 1C), HIV-1 gp120
preferentially binds to DC-SIGN. Similarly, the mono-DC-SIGN Is a DC-Specific HIV-1-Binding Protein
DC-SIGN was recently identified as a DC-specific ICAM-3 cytic cell line THP-1, which lacks expression of both
CD4 and CCR5, bound the gp120-coated beads afteradhesion receptor that mediates DC-T cell interactions
DC-SIGN Is a Novel HIV-1 trans Receptor
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Figure 2. DC-SIGN Mediates HIV-1 Infection in a DC-T Cell Coculture
(A) Antibodies against DC-SIGN inhibit HIV-1 infection as measured in a DC-T cell coculture. DC (50 3 103) were preincubated for 20 min at
room temperature with blocking mAb against CD4 (RPA-T4) or DC-SIGN (AZN-D1 and AZN-D2) (20 mg/ml) or with a combination of CCR5-
specific chemokines (CCR5 trio: RANTES, MIP-1a, and MIP1b; 500 ng/ml). Preincubated immature DC were pulsed for 2 hr with HIV-1
(M-tropic HIV-1Ba-L strain), and unbound virus particles and mAb were washed away. Subsequently, DC were cocultured with activated PBMC
(50 3 103) for 9 days. Coculture supernatants were collected, and p24 antigen levels were measured by ELISA. One representative experiment
out of two is shown.
(B) Inhibition of HIV-1 infection in a DC-T cell coculture by blocking DC-SIGN, CD4, and CCR5. HIV-1 replication in the DC-T cell coculture
at day 5 of the experiment is described in Figure 5A. The results of day 5 are representative for days 6, 7, and 9 of DC-T cell coculture. DC
were also preincubated with mAb against DC-SIGN together with anti-CD4 and CCR5-specific chemokines. p24 values represent mean 6 SD
of triplicate cultures. One representative experiment out of two is shown.
(C) DC-SIGN interactions with ICAM-3 are not involved in the transmission of DC-bound-HIV-1 to T cells. DC (50 3 103) were pulsed for 2 hr
with HIV-1 (M-tropic HIV-1Ba-L strain), washed, and cocultured with activated PBMC (50 3 103) for 9 days in the presence of the CCR5-specific
chemokines (CCR5 trio: RANTES, MIP-1a, and MIP1b; 500 ng/ml) or mAb against CD4 (RPA-T4) and DC-SIGN (AZN-D1 and AZN-D2) (20 mg/
ml). Antibodies were added post-HIV-1 infection of DC, prior to the addition of PBMC. One representative experiment out of two is shown.
it was transfected with a DC-SIGN expression vector presence of activated T cells (Figures 2A and 2B). To
determine the contribution of each of these receptors(Figure 1C). HIV-1 gp120 binding to this cell line, THP-
DC-SIGN, was also blocked by anti-DC-SIGN antibod- in this assay system, we examined the effects of anti-
bodies against CD4 and DC-SIGN and of a combinationies, but not by anti-CD4 (Figure 1D). Binding of HIV-1
gp120 to DC-SIGN expressed on DC or THP-DC-SIGN of three CCR5-specific chemokines (RANTES, MIP-1a,
and MIP-1b). Preincubation of the immature DC withwas also inhibited by the carbohydrate mannan or EGTA,
consistent with previous findings (Curtis et al., 1992) antibodies against DC-SIGN prior to infection resulted
in significant inhibition of HIV-1 replication (Figure 2A).and with the observation that DC-SIGN is homologous
to other members of the Ca21-binding mannose-type Neither anti-CD4 nor the CCR5-specific chemokines in-
hibited on their own, although a combination of theselectins (Weis et al., 1998). Together, these results dem-
onstrate that DC-SIGN is a specific dendritic cell surface did block infection of DC (Figure 2A), which is probably
due to efficient inhibition of the T cell infection by (un)-receptor for the HIV-1 envelope glycoprotein.
bound anti-CD4/chemokines. Activated T cells chal-
lenged with the same viral load exhibited a weaker infec-DC-SIGN Is Required for Efficient HIV-1 Infection
in DC-T Cell Cocultures tion than those cultured with virus-pulsed DC (data not
shown).Because DC-SIGN is exclusively expressed on DC and
has a high affinity for HIV-1 gp120, we reasoned that it Since DC-SIGN binds to ICAM-3 on T cells, it is possi-
ble that antibodies against DC-SIGN could interfere withmight play an important role in HIV-1 infection of DC or
of T cells that make contact with DC. Immature DC, the DC-T cell interaction and thereby prevent HIV-1
transmission. To examine this possibility, antibodieswhich express low levels of CD4 as well as CCR5 and
abundant DC-SIGN (Figure 1C), were pulsed with the against DC-SIGN were added after exposure of DC to
HIV-1 but prior to the addition of activated T cells. InR5 isolate HIV-1BA-L for 2 hr, washed, and cultured in the
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this setting, only CCR5-specific chemokines and anti-
CD4 antibody strongly inhibited HIV-1 infection of acti-
vated T cells, while antibodies against DC-SIGN had no
effect (Figure 2C). These results thus suggest that DC-
SIGN has an important function in propagation of HIV-1
in DC-T cell cocultures and that this function is related
to the ability of DC-SIGN to bind to gp120 and not to
its interaction with ICAM-3.
DC-SIGN Does Not Mediate HIV-1 Entry
To investigate whether DC-SIGN acts as a receptor that
permits HIV-1 entry, similar to CD4 plus CCR5, we stud-
ied HIV-1 entry into 293T cells that expressed either DC-
SIGN (293T-DC-SIGN) or CD4 and CCR5 (293T-CD4-
CCR5). Cells were pulsed overnight with HIVBA-L and
washed the next day, and p24 levels were determined.
There was no detectable p24 protein in the culture su-
pernatants harvested from 293-DC-SIGN cells several
days after the HIV-1 pulse, whereas the 293T-CD4-CCR5
cells were readily infected (Figure 3A).
To examine the possibility that DC-SIGN may work in
conjunction with either CD4 or CCR5 to permit viral
entry, we extended the studies by using HIV-1 pseu-
dotyped with the envelope glycoprotein of the R5 isolate
HIV-1ADA. We employed a replication-defective HIV-1 ge-
nome that encoded a luciferase reporter gene, which
allows a quantitative measure of the levels of single-
round infection (Figure 3B) (Deng et al., 1996). Tran-
siently transfected 293T cells expressing either CCR5
(293T-CCR5), CD4 (293T-CD4), or both (293T-CD4-
CCR5), in the presence or absence of DC-SIGN, were
infected with the reporter virus, and luciferase levels
Figure 3. DC-SIGN Expressed on Target Cells Does Not Mediatewere determined after 2 days. As observed with replicat-
HIV-1 Entrying virus, HIV-1 entry was not detected in 293T cells
(A) 293T cells were transfected with DC-SIGN or CD4 and CCR5that expressed only DC-SIGN (Figure 3B). No infection
and pulsed for 2 hr with HIV-1 (CCR5-tropic HIV-1Ba-L strain). Subse-was observed if DC-SIGN was expressed with either
quently, cells were cultured for 9 days. Supernatants were collected,CD4 or CCR5, indicating that DC-SIGN does not form
and p24 antigen levels were measured by ELISA. One representative
a complex with these molecules to permit viral entry. experiment of two is shown.
In contrast, high luciferase activity was obtained after (B) 293T cells and 293T cells stably expressing either CD4, CCR5,
or CD4 and CCR5 were transiently transfected with DC-SIGN andinfection of 293T cells expressing both CD4 and CCR5,
subsequently infected with pseudotyped CCR5-tropic HIV-1ADA virusand expression of DC-SIGN did not contribute further
in the presence of polybrene (20 mg/ml). Luciferase activity wasto viral entry into these cells (Figure 3B). Therefore, DC-
evaluated after 2 days. One representative experiment out of threeSIGN cannot substitute for CD4 or CCR5 in the process
is shown.
of HIV-1 entry.
DC-SIGN Captures HIV-1 and Facilitates Infection viral entry (Figure 4A). HIV-1 capture was completely
DC-SIGN dependent, as antibodies against DC-SIGNof HIV-1 Permissive Cells In trans
Because DC-SIGN did not appear to mediate virus entry inhibited HIV-1 infection (Figure 4A), and DC-SIGN-neg-
ative parental THP-1 cells were unable to capture andinto target cells, we hypothesized that in a DC-T cell
coculture (Figure 2) DC-SIGN might facilitate both cap- transmit HIV-1 (Figures 4A and 4B). Similar to our previ-
ous findings, the DC-SIGN-mediated infection of theture of HIV-1 on DC, independent from CD4 and CCR5,
and subsequent transmission of HIV-1 to the CD4/ target cells was not due to DC-SIGN binding to ICAM-3,
since 293T cells are ICAM-3 negative. These findingsCCR5-positive T cells. To test this, THP-DC-SIGN
transfectants, which do not express CD4 or CCR5 (Fig- indicate that DC-SIGN expressed at the surface of heter-
ologous cells can capture HIV-1 in a form that retains itsure 1C) and which cannot be infected by HIV-1 (data
not shown), were pulsed with single-round HIV-lucifer- capacity to subsequently infect HIV-1-permissive cells.
The ability of DC-SIGN to capture and transmit HIV-1ase virus pseudotyped with the HIV-1ADA envelope glyco-
protein. After washing to remove unbound virus, the was also observed with HIV-luciferase viruses pseu-
dotyped with envelope glycoproteins from an additionalcells were cocultured with CD4/CCR5-expressing 293T
cells, which are permissive for HIV-1 infection, or acti- five R5 isolates, including three primary isolates (Figure
4B), and from the X4 isolate HXB2 (data not shown).vated T lymphocytes. THP-DC-SIGN cells were able to
capture the pseudotyped virus and transmit it to the Analysis of luciferase activity in both adherent (293T-
CD4-CCR5) and nonadherent (THP-DC-SIGN) cell frac-target cells that expressed the receptors required for
DC-SIGN Is a Novel HIV-1 trans Receptor
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tions after 2 days of coculture demonstrated that pro-
ductive HIV-1 infection occured only in the HIV-1 permis-
sive 293T-CD4-CCR5 cells (data not shown). Similarly,
by using a pseudotyped HIV-1 vector with the green
fluorescent protein gene in place of Nef (HIV-eGFP), we
demonstrated that cells expressing CD4/CCR5 and not
those expressing DC-SIGN were infected in cocultures.
Thus, after coculture of virus-pulsed THP-DC-SIGN cells
with T cells, only the CD31 T cells expressed virus-
encoded GFP (Figure 4C).
Sexual transmission of HIV-1 is likely to require a
means for small amounts of virus to gain access to cells
that are permissive for viral replication. This may be
achieved because of the ability of virus to interact with
DC, which can capture HIV-1 and present it to the per-
missive cells. To mimic in vivo conditions in which HIV-1
levels are likely to be limiting, we challenged THP-1
transfectants with low titers of pseudotyped HIV-1 and
subsequently cocultured these cells with HIV-1 permis-
sive cells, without washing away unbound virus (Figure
5A). As expected, neither 293T-CD4-CCR5 cells nor acti-
vated T cells were efficiently infected with the low titers
of pseudotyped HIV-1 (Figure 5A). Strikingly, when these
permissive cells were challenged with an identical
amount of HIV-1 in the presence of THP-DC-SIGN, but
not of the parental THP-1 cells, efficient HIV-1 infection
was observed in trans (Figure 5A). The enhancement of
HIV-1 infection of primary T cells by DC-SIGN was also
observed with HIV-luciferase viruses pseudotyped with
five other R5 envelopes, including three from primary
virus isolates (Figure 5B). These results indicate that
DC-SIGN not only sequesters HIV-1 but also enhances
CD4-CCR5-mediated HIV-1 entry by presentation in trans
to the HIV-1 receptor complex. Antibodies against DC-
SIGN completely inhibited infection (Figure 5A), demon-
strating that the efficient enhancement of HIV-1 entry
into CD4/CCR5-positive cells is DC-SIGN dependent.
DC Present in Mucosal Tissues at Sites of HIV-1
Exposure Express DC-SIGN and Are CCR5 Negative
Demonstration that cells that express DC-SIGN can cap-
ture HIV-1 and efficiently transmit the virus to other cells
in trans suggested that DC that express this C-type
lectin have a key role in viral infection in vivo. To deter-
mine whether such cells are indeed present in vivo, we
performed immunohistochemical analyses of mucosalFigure 4. DC-SIGN Captures HIV-1 that Retains Infectivity for CD41
T Cells tissues that are the sites of first exposure during sexual
(A) DC-SIGN captures HIV-1 and facilitates infection of HIV-1 permis- transmission of HIV-1 (Figure 6A). DC-SIGN was ex-
sive cells in trans. DC-SIGN transfectants (100 3 103) were preincu- pressed on DC-like cells with large and very irregular
bated for 20 min at room temperature with blocking mAb against morphology that were present in the mucosal tissues,
DC-SIGN (AZN-D1 and AZN-D2; 20 mg/ml). The THP-DC-SIGN cells such as cervix, rectum, and uterus (Figures 6Aa, 6Ab,
were infected with HIV-luciferase virus pseudotyped with R5 strain
and 6Ac, respectively), in regions beneath the stratifiedHIV-1ADA Env. Alternatively activated T cells were infected with pseu-
dotyped HIV-1ADA virus. After 2 hr at 378C, the infected cells were
extensively washed and added to either 293T-CD4-CCR5 cells or
activated primary T cells (100 3 103). HIV-1 infection was determined
after 2 days by measuring the luciferase activity. One representative (C) Activated T cells are infected by HIV-1 in the T cell/THP-DC-
experiment out of three is shown. SIGN coculture. THP-DC-SIGN cells were incubated with HIV-eGFP
(B) DC-SIGN is able to mediate capture of HIV-1 viruses pseu- viruses pseudotyed with M-tropic HIV-1ADA and subsequently cocul-
dotyped with M-tropic HIV-1 envelopes from different primary iso- tured with activated T cells. The CD3-negative THP-DC-SIGN cells
lates. DC-SIGN-mediated capture was performed as described in were not infected by HIV-1, whereas the CD3-positive T cells were
(A) on 293T-CD4-CCR5 with HIV-luciferase viruses pseudotyped infected. T cells, gated by staining for CD3 (tricolor), were positive
with the CCR5-specific HIV-1 envelopes from JRFL and JRCSF and for eGFP, whereas CD3-negative THP-DC-SIGN that initially cap-
from primary viruses 92US715.6, 92BR020.4, and 93TH966.8. One tured HIV-eGFP did not express eGFP. One representative experi-
representative experiment out of two is shown. ment out of two is shown.
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infectivity during the transport from the mucosal tissues
to the T cell zones in draining lymph nodes. To determine
if virus bound to DC-SIGN retains infectivity for a pro-
longed period of time, we first conducted a time-course
experiment to determine the length of time that HIV-1
gp120 remains bound to DC-SIGN expressed on trans-
fected THP-1 cells. We observed that gp120-coated
beads remained bound to DC-SIGN for more than 60 hr
(Figure 7A). We next investigated the length of time dur-
ing which HIV-1-pulsed THP-DC-SIGN cells could retain
infectious virus. The DC-SIGN-expressing transfectants
were pulsed with pseudotyped HIV-1 for 4 hr and then
washed extensively. The pulsed cells were subsequently
placed in culture and were removed at defined intervals
and cocultured with activated T cells (Figure 7B). Re-
markably, after 4 days the HIV-1-pulsed cells were still
able to efficiently infect target cells. In contrast, virus in
the absence of DC-SIGN-positive cells lost its infectivity
after 1 day. These findings support the hypothesis that
limiting numbers of HIV-1 particles, captured by muco-
sal DC that express DC-SIGN and CD4 but not CCR5,
retain infectivity during and after migration to regional
lymphoid tissues. T cells, which express CD4 and CCR5,
would then be productively infected due to DC-SIGN-
mediated enhanced trans infectivity of the small num-
bers of HIV-1 particles (Figure 7C).
Discussion
Figure 5. DC-SIGN Enhances HIV-1 Infection of T Cells by Acting We have identified a novel DC-specific adhesion recep-
In trans tor, DC-SIGN, that is identical to the high-affinity HIV-1
At a low virus load, DC-SIGN in trans is crucial for the infection gp120-binding C-type lectin cloned from a human pla-
of HIV-1 permissive cells. THP-1 transfectants (100 3 103) were cental cDNA library (Geijtenbeek et al., 2000). We have
preincubated for 20 min at room temperature with blocking mAb
demonstrated that DC that express both DC-SIGN andagainst DC-SIGN (AZN-D1 and AZN-D2; 20 mg/ml). The cells were
CD4 preferentially use DC-SIGN to capture HIV-1 via itsinfected by low amounts of pseudotyped HIV-1ADA virus (A) or other
high affinity for HIV-1 gp120. DC-SIGN not only effi-R5 isolates of HIV-1 (B), i.e., at the threshold of detection in a single
round infection assay. After 1 hr at 378C, the cell/virus suspension ciently recruits HIV-1 but also facilitates HIV-1 infection
was directly added to either 293T-CD4-CCR5 or activated T cells of CD41 T cells by a novel in trans mechanism. Our
(100 3 103). The infectivity was determined after 2 days by measuring findings thus indicate that HIV-1 utilizes a novel receptor
the luciferase activity. One representative experiment out of two is
strategy that has not been previously described in othershown.
viral systems, and suggest that the virus exploits multi-
ple cell surface receptor systems to ensure that it can
squamous epithelium in the lamina propria. Analyses of
establish a productive infection in its host organism.
serial sections stained for CD3, CD20, CD14, and CD68
DC localized in the skin and mucosal tissues such asconfirmed that DC-SIGN-expressing cells were distinct
the rectum, uterus, and cervix have been proposed tofrom T cells, B cells, monocytes, and macrophages (data
play a role in initial HIV-1 infection. DC constitute anot shown). Similarly, in the accompanying paper (Geij-
heterogeneous population of cells that are present intenbeek et al., 2000), staining of lymph nodes and skin
minute numbers in various tissues just beneath the der-has shown DC-restricted expression of DC-SIGN. We
mis or mucosal layer and form a first-line defensehave also compared expression of DC-SIGN, CD4, and
against viruses and other pathogens. DC have pre-CCR5 on DC in the mucosa of the uterus and rectum
viously been shown to sequester HIV-1 and efficientlyand found in serial sections that the majority of DC-
transmit the virus to CD41 T cells. We have demon-SIGN-positive DC in these tissues coexpressed CD4 but
strated here that this property of DC can be ascribedlacked CCR5 (Figure 6B). This suggests that DC present
to the ability of HIV-1 to bind specifically to these cellsat mucosal sites, that have first contact with HIV-1 during
through the interaction of gp120 with DC-SIGN. DC thussexual transmission, are not infected with HIV-1 through
efficiently capture HIV-1 through a specific interactionusage of CD4/CCR5. This observation is consistent with
that is independent from binding of virus to CD4 andthe recent demonstration that DC at sites of mucosal
CCR5. DC-SIGN cannot mediate HIV-1 entry but ratherinfection of nonhuman primates do not become infected
functions as a unique HIV-1 trans receptor facilitating(Stahl-Hennig et al., 1999).
HIV-1 infection of CD4/CCR5-positive T cells (Figures 4
and 5). At low virus titer, CD4/CCR5-expressing cellsDC-SIGN-Bound HIV-1 Retains Infectivity
are not detectably infected without the help of DC-SIGNafter Long-Term Culture
in trans (Figure 5A). Conditions in which the number ofIf HIV-1 gains access to secondary lymphoid organs by
way of binding to DC, then virus would have to retain HIV-1 particles is limiting are likely to resemble those
DC-SIGN Is a Novel HIV-1 trans Receptor
593
Figure 6. DC-SIGN Is Expressed on DC Present in Mucosal Tissue that Do Not Express CCR5
Immunohistochemical analysis of DC-SIGN expression on mucosal tissue sections.
(A) Different tissue sections were stained with anti-DC-SIGN mAb: cervix (a), rectum (b), and uterus (c) (original magnification, 2003) All
mucosal tissues contain DC-SIGN-positive cells in the lamina propria. Staining of serial sections demonstrate that these DC-SIGN-positive
cells do not express CD3, CD20, CD14, and CD68 (data not shown).
(B) Immunohistochemical staining of serial sections of rectum (a±c) and uterus (d±f) with antibodies against DC-SIGN (a and d), CD4 (b and
e), or CCR5 (c and f).
found in vivo, and the results thus suggest that DC- a more efficient interaction with CD4 and/or the chemo-
SIGN may be required for viruses to be transmitted from kine receptor. As multiple conformational transitions are
mucosa to T cells that express CD4 and chemokine required before the envelope glycoprotein initiates fu-
receptors. In addition, our studies demonstrate that vi- sion with target membranes, the binding of DC-SIGN to
rus bound to DC-SIGN is remarkably stable and can gp120 may facilitate or stabilize one of these transitions.
thus retain infectivity for the prolonged periods of time Anti-gp120 antibodies that increase infectivity of viral
required for DC to traffic via lymphatics from mucosa particles have been described (Lee et al., 1997), and it
to regional lymph nodes (Figures 7A and 7B). is possible that DC-SIGN has a similar effect upon bind-
ing to the envelope glycoprotein. Alternatively, binding
of viral particles to DC-SIGN may focus or concentrateMechanism of DC-SIGN-Mediated Enhancement
them at the surface of the DC and may thus increaseof HIV-1 Infectivity
the probability that entry will occur after they bind toThe mechanisms by which HIV-1 exploits the machinery
the receptor complex on target cells. Although the mo-of DC and the properties of DC-SIGN to achieve efficient
lecular mechanism has to be investigated in more detail,infection of cells that are competent for viral replication
it is clear that DC-SIGN enhances the infection of Tremain unclear. The process through which DC-SIGN
cells, since at low multiplicity of infection T cells are notpromotes efficient infection in trans of cells through their
infected in the absence of DC-SIGN.CD4/chemokine receptor complex is of particular inter-
Whether a transient quaternary complex is formedest. Binding of the viral envelope glycoprotein to DC-
SIGN may induce a conformational change that enables between DC-SIGN, HIV-1 Env, CD4, and CCR5 remains
Cell
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Figure 7. DC-SIGN Captures HIV-1 and Retains Long-Term Infectivity
(A) Time course of HIV-1MN gp120 binding to THP-DC-SIGN. DC-SIGN-positive cells were incubated with gp120-coated beads. Beads bound
for more than 60 hr as determined by FACScan analysis.
(B) DC-SIGN binds HIV-1 and retains for more than 4 days virus that infects T cells in trans. THP/THP-SIGN cells were pulsed for 4 hr with
HIV-1 pseudotyped virus in the presence or absence of anti-DC-SIGN antibodies (AZN-D1 and AZN-D2, 20 mg/ml). After washing, the HIV-1
pulsed cells were cultured at 378C for several days. As a control, identical amounts of virus were incubated at 378C in medium without cells.
Every day, aliquots of the HIV-1 pulsed cells were added to HIV-1 permissive 293T-CD4-CCR5 cells in order to measure infectivity. Lysates
to examine luciferase activity were obtained after 2 days of coculture.
(C) Model of HIV-1 coopting DC-SIGN as a trans receptor after initial exposure. DC are the primary cells targeted by HIV-1 during mucosal
exposure and are DC-SIGN positive. HIV-1 adheres to DC-SIGN via a high-affinity interaction, and the immature DC carrying HIV-1 migrates
to the lymphoid tissues. Upon arrival, DC will cluster with T cells, and DC-SIGN enhances HIV-1 infection of T cells in trans leading to a
productive and sustained infection.
to be determined. Elucidation of the crystal structure of blocks the binding of gp120 to DC-SIGN, it is likely that
this C-type lectin binds to one or more carbohydratea gp120-CD4 complex has revealed that most glycosyla-
tion sites within gp120 reside in a ridge that flanks the moieties in gp120. It remains possible, however, that the
lectin domain of DC-SIGN interacts with the polypeptideCD4-binding pocket (Kwong et al., 1998). Since mannan
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backbone of gp120. Further studies with mutant forms that DC-SIGN is able to capture and bind to HIV-1 for
more than 4 days, after which the virus can still infectof gp120 and with soluble DC-SIGN may be informative
in efforts to elucidate the mechanism of enhanced in- permissive cells. This long-term preservation of HIV-1
in an infectious state would appear to allow sufficientfectivity in trans.
In a separate study, we have shown that DC-SIGN time for it to be transported by DC trafficking from muco-
sal surfaces to lymphoid compartments, where virusbinds to ICAM-3, which is expressed constitutively on
the surface of T lymphocytes (Geijtenbeek et al., 2000). can be transmitted (Figure 7C) (Steinman et al., 1997).
Several groups have reported that DC can migrate fromEnhancement of target cell infectivity by DC-SIGN-
bound HIV-1 was not dependent on the presence of the periphery to draining lymph nodes within 2 days after
antigen exposure or HIV-1 challenge (Barratt-Boyes etICAM-3 on target cells. However, we observed that en-
hancement of infectivity was consistently better when al., 1997; Stahl-Hennig et al., 1999). Viral particles have
been reported within endocytic vesicles of DC. This ob-target cells were T cells rather than 293-CD4-CCR5 cells.
It remains possible that the efficiency of viral transmis- servation suggests that DC-SIGN-bound HIV-1 may be
internalized and protected during the time required forsion from carrier DC to target T cells may also be en-
hanced by specific adhesive interactions other than DC- the cells to complete their journey to the regional lymph
nodes. Further studies will be required to determineSIGN-ICAM-3, such as LFA-1-ICAM-1, which predomi-
nates the adhesion between DC and activated T cells if viral internalization is essential for maintenance of
infectivity.(Geijtenbeek et al., 2000). Therefore, antibodies against
DC-SIGN do not inhibit the DC-T cell transmission of Our data suggest that, after HIV-1 has been ferried
by DC to the lymphoid compartment, DC-SIGN presentsHIV-1 postinfection (Figure 2C).
the bound viral particles to the CD4/CCR5 complex
present on T cells and greatly enhances their entry intoRole of DC in HIV Infection In Vivo
these cells (Figure 7C). We showed that monoclonalThe only HIV-1 receptors previously known to have a
antibodies directed against DC-SIGN blocked produc-role in HIV-1 entry were CD4 and a subset of the G
tive infection occurring in the T cell cocultures with CD4/protein±coupled chemokine receptors, including CCR5
CCR5-positive monocyte-derived DC. Therefore, evenand CXCR4. CCR5 functions as the major receptor for
in the presence of obligatory HIV-1 receptors presentstrains of virus previously classified as ªmacrophage-
in cis on target cells, DC-SIGN functions as a transtropic,º and only those strains that can utilize this che-
receptor for HIV-1 infection of T cells and is critical inmokine receptor can be efficiently transmitted between
the primary cocultures. This is an important example ofindividuals (Littman, 1998). Other gp120-binding recep-
how a receptor can work in trans. Interestingly, CD4tors had been previously identified, including DC-SIGN
can facilitate HIV-1 infection of CD4-negative cells thatand galactosyl ceramide (Harouse et al., 1991), but these
express CCR5 by a trans receptor mechanism, althoughhad not been shown to be involved in viral entry. This
it remains unclear whether this is an important routestudy shows that DC-SIGN not only binds HIV-1 but can
of infection in vivo (Speck et al., 1999). In that case,also sequester it and catalyze its entry into cells that
interaction of envelope glycoprotein with CD4 results inexpress CD4 and chemokine receptors. Although it re-
mains to be determined whether DC-SIGN has a signifi- a conformational change that permits binding of the
virus to CCR5 on CD4-negative cells. Together with thecant role in HIV-1 pathogenesis in vivo, our in vitro re-
sults and the pattern of expression of the different results presented here, these studies indicate that HIV-1
can use receptors in trans to facilitate infection of cellsreceptors in mucosal tissues are consistent with its hav-
ing a key function in the early stages of viral infection. that otherwise may be difficult to infect either because of
lack of proper receptors or because of their anatomicalRemarkably, our immunohistochemical analyses clearly
demonstrate that CCR5 is not expressed in the lamina distribution relative to the sites of HIV-1 exposure.
The discovery of the role of DC-SIGN in HIV-1 infectionpropria of HIV-1-related mucosal tissue (Figure 6),
whereas DC-SIGN is abundantly expressed. This obser- may have significant implications for understanding the
mechanism of HIV-1 transmission and for developingvation confirms and extends the findings of Hladik et
al. (1999), who showed that DC present in the genital strategies to prevent or block viral infection. The obser-
vation that transmission of infection is confined to R5tract also lack CCR5, and strongly suggest that HIV-1
cannot infect DC present at mucosal sites. strains of HIV-1 has remained a major enigma. In prelimi-
nary studies, we found that DC-SIGN captures and en-DC-SIGN may therefore play a crucial role in initial
HIV-1 exposure by mediating viral binding to DC present hances infection of both X4 and R5 strains, and it is
thus unlikely that preferential interaction of DC-SIGNin mucosal tissues, rather than infection of these cells.
The high level of expression of DC-SIGN on immature with CCR5 would account for the restriction in tropism
during transmission. Nevertheless, the demonstrationDC and its high affinity for gp120, which exceeds that
of CD4 (Curtis et al., 1992), indicate that DC-SIGN is that uninfected DC contribute to the process of viral
entry raises the possibility that the requirement for CCR5endowed with the ability to efficiently capture HIV-1,
even when the virus is present in minute amounts. HIV-1 utilization may reflect a requirement for interaction of
multiple cell types. The inhibition of HIV-1 infection ob-may subsequently exploit the migratory capacity of
the DC to gain access to the T cell compartment in served in the presence of anti-DC-SIGN antibodies sug-
gests that interfering with the gp120-DC-SIGN interac-lymphoid tissues. DC must be activated to commence
their migration, and it is hence possible that multimeriza- tion either during the capture phase of DC in the mucosa
or during DC/T cell interactions in lymphoid organstion of DC-SIGN on the cell surface of DC by interaction
with the multivalent virus particles may initiate this pro- could inhibit dissemination of the virus. Small molecule
inhibitors, potentially carbohydrate-based, that blockcess. Interestingly, the time course experiment shows
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stomatitis virus glycoprotein (VSV-G) were used to ensure targetthe ability of gp120 to bind to DC-SIGN may be effective
cell viability.in prophylaxis or therapeutic intervention. Vaccine strat-
Immunohistochemical analyses were performed as describedegies aimed at eliciting mucosal antibodies that inhibit
previously (Geijtenbeek et al., 2000).
gp120 binding to DC-SIGN may also be efficacious in
preventing early establishment of infection. The efficacy Acknowledgments
of gp120 vaccines has been measured as a function of
This work was supported by the Dutch Cancer Society (the NKB)the levels of neutralizing antibodies that inhibit HIV entry
(grant number 96-1358), the Netherlands Organization for Scientificthrough CD4 and CCR5. Our results thus suggest that
Research (the NWO) (grant number 901-09-244), and the Technologylevels of antibodies that block virus binding to DC-SIGN
Foundation (the STW) (grant number NGN.4187). V. N. K. is a fellow
or the DC-SIGN-mediated enhancement of infection of the Damon Runyon-Walter Winchell Foundation, and D. R. L. is
may also be predictive of protection. an investigator of the Howard Hughes Medical Institute and was
supported in this project by the National Institutes of Health grant
AI33856. We also thank H. Jacobs for the generation of THP-DC-Experimental Procedures
SIGN cells. We are grateful to Dr. D. J. Ruiter and Dr. G. N. Muijen
for their advice on the immunohistochemical analyses and Dr. H.Antibodies
Schuitemaker and Dr. N. Kootstra for their helpful discussions.The following mAb were used: 2D7 (anti-CCR5; Becton Dickinson
and Co., Oxnard, CA) and CD4 (RPA-T4; PharMingen, San Diego,
Received November 30, 1999; revised January 19, 2000.CA). Anti-DC-SIGN mAb AZN-D1 and AZN-D2 were obtained by
screening hybridoma supernatants of human DC-immunized BALB/c
Referencesmice for the ability to block adhesion of DC to ICAM-3, as measured
by the fluorescent bead adhesion assay.
Adema, G.J., Hartgers, F., Verstraten, R., de Vries, E., Marland, G.,
Menon, S., Foster, J., Xu, Y., Nooyen, P., McClanahan, T., et al.Cells
(1997). A dendritic-cell-derived C-C chemokine that preferentiallyImmature DC were cultured as previously described (Geijtenbeek
attracts naive T cells. Nature 387, 713±717.et al., 2000). Stable THP-1 transfectants expressing DC-SIGN were
Ayehunie, S., Garcia-Zepeda, E.A., Hoxie, J.A., Horuk, R., Kupper,generated by transfection of THP-1 cells with pRc/CMV-DC-SIGN
T.S., Luster, A.D., and Ruprecht, R.M. (1997). Human immunodefi-by electroporation similarly as described (Lub et al., 1997).
ciency virus-1 entry into purified blood dendritic cells through CC
and CXC chemokine coreceptors. Blood 90, 1379±1386.Fluorescent Bead Adhesion Assay
Banchereau, J., and Steinman, R.M. (1998). Dendritic cells and theCarboxylate-modified TransFluorSpheres (488/645 nm, 1.0 mm; Mo-
control of immunity. Nature 392, 245±252.lecular Probes, Eugene, OR) were coated with M-tropic HIV-1MN
envelope glycoprotein gp120 similarly as was described for ICAM-1 Barratt-Boyes, S.M., Watkins, S.C., and Finn, O.J. (1997). In vivo
beads (Geijtenbeek et al., 1999). Streptavidin-coated beads were migration of dendritic cells differentiated in vitro: a chimpanzee
incubated with biotinylated F(ab9)2 fragment rabbit anti-sheep IgG model. J. Immunol. 158, 4543±4547.
(6 mg/ml; Jackson Immunoresearch) followed by an overnight incu- Bjorndal, A., Deng, H., Jansson, M., Fiore, J.R., Colognesi, C., Karls-
bation with sheep-anti-gp120 antibody D7324 (Aalto Bio Reagents son, A., Albert, J., Scarlatti, G., Littman, D.R., and Fenyo, E.M. (1997).
Ltd., Dublin, Ireland) at 48C. The beads were washed and incubated Coreceptor usage of primary human immunodeficiency virus type
with 250 ng/ml purified HIV-1 gp120 (provided by Immunodiagnos- 1 isolates varies according to biological phenotype. J. Virol. 71,
tics, Inc., through the NIH AIDS Research and Reference Reagent 7478±7487.
Program) overnight at 48C. The fluorescent beads adhesion assay
Blauvelt, A., Asada, H., Saville, M.W., Klaus-Kovtun, V., Altman, D.J.,was performed as described by Geijtenbeek et al. (1999).
Yarchoan, R., and Katz, S.I. (1997). Productive infection of dendritic
cells by HIV-1 and their ability to capture virus are mediated through
HIV-1 Infection of Both DC and DC-SIGN Transfectants separate pathways. J. Clin. Invest. 100, 2043±2053.
The M-tropic strain HIV-1Ba-L was grown to high titer in monocyte-
Cameron, P.U., Freudenthal, P.S., Barker, J.M., Gezelter, S., Inaba,derived macrophages (MDM). Seven days after titration of the virus
K., and Steinman, R.M. (1992). Dendritic cells exposed to humanstock on MDM, TCID50 was determined with a p24 antigen ELISA
immunodeficiency virus type-1 transmit a vigorous cytopathic infec-(Diagnostics Pasteur, Marnes la Coquette, France) and estimated
tion to CD41 T cells. Science 257, 383±387.as 104/ml. DC (50 3 103) preincubated with mAb against DC-SIGN
Cameron, P.U., Lowe, M.G., Crowe, S.M., O'Doherty, U., Pope, M.,(AZN-D1 and AZN-D2) or CD4 (RPA-T4) (20 mg/ml) or a combination
Gezelter, S., and Steinman, R.M. (1994). Susceptibility of dendriticof CCR5-specific chemokines (RANTES, MIP-1a, MIP-1b; each 500
cells to HIV-1 infection in vitro. J. Leukoc. Biol. 56, 257±265.ng/ml) for 20 min at room temperature were pulsed for 2 hr with
HIV-1Ba-L (at a multiplicity of infection of 103 infectious units per 105 Cameron, P., Pope, M., Granelli-Piperno, A., and Steinman, R.M.
cells), washed, and cocultured with activated PBMC (50 3 103). (1996). Dendritic cells and the replication of HIV-1. J. Leukoc. Biol.
No DC-T cell syncytium formation was observed. The postinfection 59, 158±171.
experiment was performed similarly except that the mAb or chemo- Canque, B., Bakri, Y., Camus, S., Yagello, M., Benjouad, A., and
kines were added after the washing step of the HIV-1 pulse, together Gluckman, J.C. (1999). The susceptibility to X4 and R5 human immu-
with the activated PBMC. Culture supernatants were collected at nodeficiency virus-1 strains of dendritic cells derived in vitro from
day 5, 6, 7, and 9 after DC-T cell coculture and p24 antigen levels, CD34(1) hematopoietic progenitor cells is primarily determined by
as a measure of HIV-1 production were determined by a p24 antigen their maturation stage. Blood 93, 3866±3875.
ELISA. PBMC were activated by culturing them in the presence of
Chan, D.C., and Kim, P.S. (1998). HIV entry and its inhibition. CellIL-2 (10 U/ml) and PHA (10 mg/ml) for 2 days.
93, 681±684.Pseudotyped viral stocks were generated by calcium-phosphate
Curtis, B.M., Scharnowske, S., and Watson, A.J. (1992). Sequencetransfections of 293T cells with the proviral plasmid pNL-Luc-E2R2
and expression of a membrane-associated C-type lectin that exhib-(containing a luciferase reporter gene) or the proviral pHIV-eGFP
its CD4-independent binding of human immunodeficiency virus en-(containing a GFP reporter gene) and expression plasmids for ADA,
velope glycoprotein gp120. Proc. Natl. Acad. Sci. USA 89, 8356±JRFL, and JRCSF gp160 envelopes. The isolation, identification,
8360.and construction of the plasmids encoding the primary virus enve-
lopes from 92US715.6, 92BR020.4, and 93TH966.8 has been pre- Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M.,
Di Marzio, P., Marmon, S., Sutton, R.E., Hill, C.M., et al. (1996).viously described (Bjorndal et al., 1997). Viral stocks were evaluated
by limiting dilution on 293T-CD4-CCR5 cells. HIV-1 pseudotyped Identification of a major co-receptor for primary isolates of HIV-1.
Nature 381, 661±666.with murine leukemia virus (MLV), amphotropic Env, and vesicular
DC-SIGN Is a Novel HIV-1 trans Receptor
597
Dragic, T., Litwin, V., Allaway, G.P., Martin, S.R., Huang, Y., Naga- lymphoid tissue with simian immunodeficiency virus. Science 285,
1261±1265.shima, K.A., Cayanan, C., Maddon, P.J., Koup, R.A., Moore, J.P., et
al. (1996). HIV-1 entry into CD41 cells is mediated by the chemokine Steinman, R.M., and Inaba, K. (1999). Myeloid dendritic cells. J.
receptor CC-CKR-5. Nature 381, 667±673. Leukoc. Biol. 66, 205±208.
Fauci, A.S. (1996). Host factors and the pathogenesis of HIV-induced Steinman, R.M., Pack, M., and Inaba, K. (1997). Dendritic cells in
disease. Nature 384, 529±534. the T-cell areas of lymphoid organs. Immunol. Rev. 156, 25±37.
Geijtenbeek, T.B., van Kooyk, Y., van Vliet, S.J., Renes, M.H., Ray- Valitutti, S., Muller, S., Cella, M., Padovan, E., and Lanzavecchia, A.
makers, R.A., and Figdor, C.G. (1999). High frequency of adhesion (1995). Serial triggering of many T-cell receptors by a few peptide-
defects in B-lineage acute lymphoblastic leukemia. Blood 94, MHC complexes. Nature 375, 148±151.
754±764. Weis, W.I., Taylor, M.E., and Drickamer, K. (1998). The C-type lectin
Geijtenbeek, T.B., Torensma, R., van Vliet, S.J., van Duijnhoven, superfamily in the immune system. Immunol. Rev. 163, 19±34.
G.C., Adema, G.J., van Kooyk, Y., and Figdor, C.G. (2000). Identifica- Weissman, D., Li, Y., Ananworanich, J., Zhou, L.J., Adelsberger, J.,
tion of DC-SIGN, a novel dendritic cell±specific ICAM-3 receptor Tedder, T.F., Baseler, M., and Fauci, A.S. (1995). Three populations
that supports primary immune responses. Cell 100, 575±585. of cells with dendritic morphology exist in peripheral blood, only
Granelli-Piperno, A., Moser, B., Pope, M., Chen, D., Wei, Y., Isdell, one of which is infectable with human immunodeficiency virus type
F., O'Doherty, U., Paxton, W., Koup, R., Mojsov, S., et al. (1996). 1. Proc. Natl. Acad. Sci. USA 92, 826±830.
Efficient interaction of HIV-1 with purified dendritic cells via multiple
chemokine coreceptors. J. Exp. Med. 184, 2433±2438.
Granelli-Piperno, A., Delgado, E., Finkel, V., Paxton, W., and
Steinman, R.M. (1998). Immature dendritic cells selectively replicate
macrophagetropic (M-tropic) human immunodeficiency virus type
1, while mature cells efficiently transmit both M- and T-tropic virus
to T cells. J. Virol. 72, 2733±2737.
Granelli-Piperno, A., Finkel, V., Delgado, E., and Steinman, R.M.
(1999). Virus replication begins in dendritic cells during the transmis-
sion of HIV-1 from mature dendritic cells to T cells. Curr. Biol. 9,
21±29.
Grouard, G., and Clark, E.A. (1997). Role of dendritic and follicular
dendritic cells in HIV infection and pathogenesis. Curr. Opin. Immu-
nol. 9, 563±567.
Harouse, J.M., Bhat, S., Spitalnik, S.L., Laughlin, M., Stefano, K.,
Silberberg, D.H., and Gonzalez-Scarano, F. (1991). Inhibition of entry
of HIV-1 in neural cell lines by antibodies against galactosyl cera-
mide. Science 253, 320±323.
Hladik, F., Lentz, G., Akridge, R.E., Peterson, G., Kelley, H., McElroy,
A., and McElrath, M.J. (1999). Dendritic cell-T-cell interactions sup-
port coreceptor-independent human immunodeficiency virus type
1 transmission in the human genital tract. J. Virol. 73, 5833±5842.
Kwong, P.D., Wyatt, R., Robinson, J., Sweet, R.W., Sodroski, J.,
and Hendrickson, W.A. (1998). Structure of an HIV gp120 envelope
glycoprotein in complex with the CD4 receptor and a neutralizing
human antibody. Nature 393, 648±659.
Lee, S., Peden, K., Dimitrov, D.S., Broder, C.C., Manischewitz, J.,
Denisova, G., Gershoni, J.M., and Golding, H (1997). Enhancement
of human immunodeficiency virus type 1 envelope-mediated fusion
by a CD4-gp120 complex-specific monoclonal antibody. J. Virol.
71, 6037±6043.
Littman, D.R. (1998). Chemokine receptors: keys to AIDS pathogene-
sis? Cell 93, 677±680.
Lu, Z., Berson, J.F., Chen, Y., Turner, J.D., Zhang, T., Sharron, M.,
Jenks, M.H., Wang, Z., Kim, J., Rucker, J., et al. (1997). Evolution
of HIV-1 coreceptor usage through interactions with distinct CCR5
and CXCR4 domains. Proc. Natl. Acad. Sci. USA 94, 6426±6431.
Lub, M., van Vliet, S.J., Oomen, S.P., Pieters, R.A., Robinson, M.,
Figdor, C.G., and van Kooyk, Y. (1997). Cytoplasmic tails of beta 1,
beta 2, and beta 7 integrins differentially regulate LFA-1 function in
K562 cells. Mol. Biol. Cell 8, 719±728.
Rowland-Jones, S.L. (1999). HIV: the deadly passenger in dendritic
cells. Curr. Biol. 9, R248±R250.
Rubbert, A., Combadiere, C., Ostrowski, M., Arthos, J., Dybul, M.,
Machado, E., Cohn, M.A., Hoxie, J.A., Murphy, P.M., Fauci, A.S., et
al. (1998). Dendritic cells express multiple chemokine receptors used
as coreceptors for HIV entry. J. Immunol. 160, 3933±3941.
Speck, R.F., Esser, U., Penn, M.L., Eckstein, D.A., Pulliam, L., Chan,
S.Y., and Goldsmith, M.A. (1999). A trans-receptor mechanism for
infection of CD4-negative cells by human immunodeficiency virus
type 1. Curr. Biol. 9, 547±550.
Stahl-Hennig, C., Steinman, R.M., Tenner-Racz, K., Pope, M., Stolte,
N., Matz-Rensing, K., Grobschupff, G., Raschdorff, B., Hunsmann,
G., and Racz, P. (1999). Rapid infection of oral mucosal-associated
